Tue, Nov 26, 2024
5 stocks to buy for short term: The stock market rallied for the third consecutive day today amid fresh foreign fund inflows and firm trends in the US markets. Amid this, brokerage firm Axis Direct has advised positional traders to buy five stocks for the next 15 days.
More >
Wed, Oct 02, 2024
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing.
Mon, Sep 30, 2024
Which stocks will be in focus today including JSW Infra, Tolins Tyres, Manba Finance, LUPIN, Zydus Lifesciences? On the basis of which news there will be action in the market? What are the important triggers for the market?
Sat, Sep 28, 2024
The group now has 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Tue, Sep 17, 2024
In August this year when Zydus acquired a 50 per cent stake in Sterling Biotech Ltd (SBL), the company negotiated for the right to acquire the 'Target Business' of SBL at a pre-defined value.
Wed, Aug 28, 2024
Zydus Lifesciences traded with gains after Jefferies double upgraded the counter.
Sat, Aug 24, 2024
The acquisition also marks Zydus' foray into specialised biotech products for health and nutrition, specifically catering to consumers who prefer animal-free protein or suffer from lactose intolerance, the Gujarat-based firm said.
Fri, Aug 09, 2024
Zydus Lifesciences reports a 31% year-on-year increase in consolidated net profit to ₹1,420 crore for Q1 FY25, driven by robust sales growth. Revenue surged to ₹6,207 crore, up from ₹5,140 crore in the previous year. Strong performance in the US and India markets, along with a strategic focus on sustainable growth and innovation, underscores the company’s positive outlook for the fiscal year. Shares closed 1.91% higher at ₹1,304.
Wed, Jul 31, 2024
Following the approval by Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), for Mamitra, the drug will be marketed in different strengths of 150 mg and 440 mg, Zydus Lifesciences said in a regulatory filing.
Thu, Jul 18, 2024
Zydus Lifesciences Share Price NSE, BSE: Zydus Lifesciences has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India.
Fri, Jul 05, 2024
Stock Market: The domestic stock market had a weak start on Friday (July 5). There is selling pressure in banking shares. Amid the market decline, brokerage firm Motilal Oswal has made pharma sector giant Zydus Lifesciences a technical pick. Brokerage has advised buying in Zydus lifescience for 2-3 days.
Thu, Jul 04, 2024
Zydus Lifesciences Share Price Target: Anil Singhvi has advised investors to buy this pharma stock when it is available in the range of Rs 1,100.
The tentative approval by the US Food and Drug Administration (USFDA) is for Azilsartan Medoxomil tablets of strengths 40 mg and 80 mg, Zydus Lifesciences said in a regulatory filing.
Fri, Jun 14, 2024
The tentative approval by the US Food and Drug Administration (USFDA) is for Azilsartan Medoxomil and Chlorthalidone tablets of strengths 40 mg/12.5 mg and 40 mg/25 mg, Zydus Lifesciences said in a regulatory filing.
Sat, May 18, 2024
Zydus Lifesciences (ZYDUSLIFE) shares scaled a record high in a special trading session on Saturday, May 18, after the pharmaceutical company staged a better-than-expected quarterly financial performance.
Mon, May 13, 2024
Healthcare stocks have been one of the stock gainers in the last one years. Their rise quickened specially after the coronavirus pandemic when the demand for medicines and healthcare facilities increased many folds.
Sun, May 12, 2024
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders.
Thu, May 09, 2024
The final approval by the US Food and Drug Administration (USFDA) is for Dapsone gel of strength 7.5 per cent, Zydus Lifesciences said in a regulatory filing.
Wed, Apr 24, 2024
The US Food and Drug Administration (USFDA) inspected the facility at Jarod near Vadodara from April 15 to April 23, the drug maker said in a regulatory filing.
Mon, Apr 22, 2024
Zydus Lifesciences (ZYDUSLIFE) share price news: Zydus Lifesciences (ZYDUSLIFE) shares jumped after the Ahmedabad-headquartered pharmaceutical company launched Mirabegron extended-release tablets in the strength of 25 mg in the US. The 25 mg and 50 mg strengths of the Mirabegron ER tablets have estimated annual sales of $2.4 billion in the US, according to IQVIA MAT data.
Fri, Mar 22, 2024
Holi Stocks 2024: Ahead of Holi on March 25, 2024 (Monday), brokerage Sharekhan has picked five stocks with strong fundamentals for more than 12 months. The shares include Dalmia Bharat, Zydus Lifesciences, Coal India, HUL, and Ashok Leyland. As per the brokerage's targets, investors can get returns of up to 36 per cent.
Tue, Feb 27, 2024
The share repurchase programme will close on March 6, 2024, the drug firm said in a regulatory filing.
Tue, Dec 26, 2023
Zydus Lifesciences on Tuesday said its arm Zydus Healthcare Ltd has been served an income tax notice demand of Rs 284.58 crore for for the assessment year 2023-2024.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
